Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System

Related articles

1. Interim BNT162b2 LP.8.1-adapted COVID-19 Vaccine Effectiveness among Non-Immunocompromised Adults ≥65 years of age in California and Louisiana, August–December 2025

   This article has 10 authors:

   1. Laura D. Zambrano
   2. Tiange Yu
   3. Jazmine Mateus
   4. Xin Zhao
   5. Kathleen M. Andersen
   6. Srinivas R. Valluri
   7. Burcu Karakuzu Ikizler
   8. Rajeev M. Nepal
   9. Adam MacNeil
   10. Hannah R. Volkman

2. The potential health and economic impact of introducing the vaccine candidate VPM1002 to prevent tuberculosis disease in low- and middle-income countries: a modelling study

   This article has 8 authors:

   1. Rebecca A Clark
   2. Allison Portnoy
   3. Tom Sumner
   4. Daniel J Grint
   5. Tomos O Prŷs-Jones
   6. Roel Bakker
   7. Nicolas A Menzies
   8. Richard G White

3. Healthy vaccinee effect in SARS-CoV-2 vaccinees without documented infection

   This article has 4 authors:

   1. Uwe Riedmann
   2. Hermann Brenner
   3. John P.A. Ioannidis
   4. Stefan Pilz